Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
Formulary messaging clarification
-
Hi there,
I’m seeking clarification on the rules around formulary messaging. Specifically:
-
I understand that therapeutic claims must be separate from formulary information, but can both appear within the same piece as long as they are clearly distinct?
-
Are formulary claims permitted to be combined with non-therapeutic messages (ex: experience claims)?
-
Finally, can formulary messaging be directed to patients to inform them of coverage in their province? I understand that this is acceptable in a DTC context, but I’d like to confirm whether this is also permitted in patient-directed materials (ex: “Now covered on ODB”).
Thank you for your guidance.
Adelaide
-
-
Hey @adelaidebaker
- Yes.
- Experience claims should not be positioned in a manner which suggests significance to the listing or vise versa. It cannot be stated or inferred that the experience is linked to coverage or that coverage is due to the experience.
- Patient information should be informational and not promotional. The copy “Now covered on ODB” would be considered promotional. For acceptable communications around formulary coverage, see Guidance on branded patient information section 1.3 Formulary Statements.
-
Thank you!
